Open an account

KALA BIO

KALA · NASDAQ

$0.1897−$0.0029 (−1.51%)TodayMarket closed ·
Prev close $0.1926

KALA analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Mar 20, 2026

Bull case

Kala Bio Inc. has established a 35% probability of approval for its lead product candidate, KPI-012, potentially enhancing its market viability as it aligns with comparable pricing models such as that of OXERVATE. The company posits that more frequent dosing at elevated levels may lead to improved efficacy results, which could further bolster the likelihood of favorable outcomes in the ongoing CHASE trial. This strategic approach is expected to reduce the placebo response and increase the chances of achieving the primary endpoint of complete healing in the treatment of primary corneal epithelial defect (PCED).

Bear case

Kala Bio Inc. faces significant concerns regarding the potential efficacy and regulatory approval of its primary product candidate, KPI-012, as clinical trials may be hampered by high placebo response rates, leading to the possibility of missing primary endpoints. Additionally, the company is exposed to inherent risks, including the failure of KPI-012 in clinical trials, challenges in obtaining regulatory approval, and issues related to market penetration and competition that could hinder commercial success. Furthermore, the specter of dilution risk adds another layer of uncertainty for investors, potentially impacting the company's financial stability moving forward.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.